Antiretroviral Therapy through Barriers： A Prominent Role for Nanotechnology in HIV-1 Eradication from Sanctuaries  

作　　者：Fabio Corsi Luca Sorrentino Serena Mazzucchelli Marta Truffi Amedeo Capetti Giuliano Rizzardini Luisa Fiandra 

机构地区：[1]Universit3 degli Studi di Milano, Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", via G.B. Grassi 74, 20157, Milan,ltalia [2]Ospedale L. Sacco, via G.B. Grassi 74, 20157, Milan, Italia [3]University of the Witwatersrand, Faculty of Health Science, School of Clinical Medicine, 7 York Rd & Carse O'Gowrie Road,Johannesburg, South Africa

出　　处：《Journal of Pharmacy and Pharmacology》2016年第7期328-340,共13页药剂与药理学（英文版）

摘　　要：Abstract： In HIV-1 management, eradication of the virus from sanctuaries represents a major and challenging goal. The genital tract, gut associated lymphoid tissue, lymph nodes, central nervous system, macrophages and latently infected CD4＋ T lymphocytes are typical sites where H1V-1 compartmentalizes. To circumvent this problem, a consistent number of studies have focused on improving ARVs （antiretroviral drugs） delivery into sanctuary sites and different nanoteehnological approaches have been developed. Cellular HIV-1 sanctuaries （i.e. macrophages） can be reached by nanoformulation of ARVs or by activation of latently infected cells. Anatomical sanctuaries （i.e. brain or male genital tract） can be addressed by increasing the permeation of ARVs across tissue barriers, such as the blood-brain barrier or the blood-testis barrier, while ARVs concentration in lymph nodes can be enhanced by drug encapsulation in CD4-targeted nanoparticles.

关 键 词：NANOTECHNOLOGY HIV-1 ANTIRETROVIRALS SANCTUARIES delivery. 

分 类 号：S859.79[农业科学—临床兽医学] Q78[农业科学—兽医学]